FDG-PET/CT based response-adapted treatment

Cancer Imaging

Volumn 12, Issue 2, 2012, Pages 324-335

  De Geus Oei, Lioe Fee ^a   Vriens, Dennis ^a   Arens, Anne I J ^a   Hutchings, Martin ^b   Oyen, Wim J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Rigshospitalet   (Denmark)

Author keywords

18f fluorodeoxyglucose; Breast cancer; Gastroesophageal cancer; Malignant lymphoma; Metabolic response adjusted therapy; PET guided treatment; Positron emission tomography; Randomized controlled trials; Risk adapted treatment

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; PROCARBAZINE; RITUXIMAB; VINBLASTINE; VINCRISTINE; VINCRISTINE SULFATE;

ADENOCARCINOMA; ADVANCED CANCER; BREAST CANCER; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGOGASTRIC ADENOCARCINOMA; GASTROESOPHAGEAL CANCER; HODGKIN DISEASE; HUMAN; LYMPHOMA; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; REVIEW; RISK ASSESSMENT; SOLID TUMOR; STOMACH CANCER; TREATMENT RESPONSE;

ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84867919564     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2012.9006     Document Type: Review

References (79)

1. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106-1110. doi:10.1136/bmj.39500.677199.AE. PMid:18483053.
2. 18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752. doi:10.1200/JCO.2007.11.6525. PMid:17646666.
3. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma 2009; 50: 1257-1260. doi:10.1080/10428190903040048. PMid:19544140.
4. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25: 571-578. doi:10.1200/JCO.2006.08.2305. PMid:17242397.
5. Le Roux PY, Gastinne T, Le Gouill S, et al. Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Eur J Nucl Med Mol Imaging 2011; 38: 1064-1071. doi:10.1007/s00259-011-1741-0. PMid:21308370.
6. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 52-59. doi:10.1182/blood-2005-06-2252. PMid:16150944.
7. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica 2006; 91: 475-481. PMid:16585014.
8. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer 2006; 107: 2678-2687. doi:10.1002/cncr.22276. PMid:17063502.
9. 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007; 48: 1626-1632. doi:10.2967/jnumed.107.042093. PMid:17873129.
10. 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009; 50: 527-533. doi:10.2967/jnumed.108.057703. PMid:19289424.
11. Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. J Nucl Med 2007; 48(Suppl 1): 19S-27S. PMid:17204717.
12. Mikhaeel NG, Timothy AR, O'Doherty MJ, Hain S, Maisey MN. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma - comparison with CT. Leuk Lymphoma 2000; 39: 543-553. doi:10.3109/ 10428190009113384. PMid:11342337.
13. Dupuis J, Itti E, Rahmouni A, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18-fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol 2009; 20: 503-507. doi:10.1093/annonc/mdn671. PMid:19074215.
14. 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Haematologica 2000; 85: 613-618. PMid:10870118.
15. Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13: 1356-1363. doi:10.1093/annonc/mdf256. PMid:12196360.
16. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med 2002; 43: 1018-1027. PMid:12163626.
17. Torizuka T, Nakamura F, Kanno T, et al. Early therapy monitoring with FDG-PET in aggressive non-Hodgkin's lymphoma and Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 22-28. doi:10.1007/s00259-003-1333-8. PMid:14574514.
18. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 1514-1523. doi:10.1093/annonc/mdi272. PMid:15980161.
19. 18F]fluoro-2-deoxy-D- glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 1376-1381. doi:10.1182/blood-2005-01-0272. PMid:15860666.
20. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005; 16: 1160-1168. doi:10.1093/annonc/mdi200. PMid:15939713.
21. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol 2006; 17: 1296-1300. doi:10.1093/annonc/mdl122. PMid:16766583.
22. Fruchart C, Reman O, Le Stang N, et al. Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study. Leuk Lymphoma 2006; 47: 2547-2557. doi:10.1080/10428190600942959. PMid:17169799.
23. Markova J, Kobe C, Skopalova M, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Ann Oncol 2009; 20: 1270-1274. doi:10.1093/annonc/mdn768. PMid:19228806.
24. Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010; 51: 1337-1343. doi:10.2967/jnumed.109.073197. PMid:20720036.
25. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009; 27: 1906-1914. doi:10.1200/JCO.2008.16.0861. PMid:19273713.
26. Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009; 50: 1761-1764. doi:10.3109/ 10428190903308072. PMid:19883305.
27. Andre M, Vander Borght T, Bosly A. Interim FDG-PET scan in Hodgkin's lymphoma: hopes and caveats. Adv Hematol 2011; 2011: 430679. PMid:21234093.
28. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003; 21: 3431-3439. doi:10.1200/JCO.2003.07. 131. PMid:12885835.
29. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905-909. doi:10.1182/blood-2006-04-019901. PMid:17018856.
30. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003; 21: 3601-3608. doi:10.1200/JCO.2003.03.023. PMid:12913100.
31. Girinsky T, van der Maazen R, Specht L, et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006; 79: 270-277. doi:10.1016/j.radonc.2006.05.015. PMid:16797755.
32. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005; 23: 4634-4642. doi:10.1200/JCO.2005.09.085. PMid:15837968.
33. Straus DJ, Portlock CS, Qin J, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 3483-3489. doi:10.1182/blood-2004-04- 1311. PMid:15315964.
34. Sher DJ, Mauch PM, Van den Abbeele A, LaCasce AS, Czerminski J, Ng AK. Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy. Ann Oncol 2009; 20: 1848-1853. doi:10.1093/annonc/mdp071. PMid:19541793.
35. PET scan in planning treatment in patients undergoing combination chemotherapy for stage IA or stage IIA Hodgkin lymphoma. 2010. doi:10.1093/annonc/mdp071. Available at: http://clinicaltrials.gov/ct2/show/ NCT00943423.
36. HD16 for early stages - treatment optimization trial in the first-line treatment of early stage Hodgkin lymphoma; treatment stratification by means of FDG-PET. 2011. doi:10.1093/annonc/mdp071. Available at: http://clinicaltrials. gov/ct2/show/NCT00736320.
37. Fludeoxyglucose F 18 PET scan-guided therapy or standard therapy in treating patients with previously untreated stage I or stage II Hodgkin's lymphoma. 2011. doi:10.1093/annonc/mdp071. Available at: http://clinicaltrials. gov/ct2/show/NCT00433433.
38. Response-based therapy assessed by PET scan in treating patients with bulky stage I and stage ii classical Hodgkin lymphoma. 2012. doi:10.1093/annonc/mdp071. Available at: http://clinicaltrials.gov/ct2/show/ NCT01118026.
39. Chemotherapy based on positron emission tomography scan in treating patients with stage I or stage II Hodgkin lymphoma. 2012. doi:10.1093/annonc/ mdp071. Available at: http://clinicaltrials.gov/ct2/show/NCT01132807.
40. Advani R, Maeda L, Lavori P, et al. Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease. J Clin Oncol 2007; 25: 3902-3907. doi:10.1200/JCO.2007.11.9867. PMid:17664458.
41. Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med 2011; 365: 203-212. doi:10.1056/NEJMoa1100340. PMid:21774708.
42. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 2009; 27: 4548-4554. doi:10.1200/JCO.2008.19.8820. PMid:19704068.
43. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced highrisk Hodgkin's lymphoma. Ann Oncol 2010; 21: 126-132. doi:10.1093/annonc/mdp271. PMid:19608615.
44. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003; 348: 2386-2395. doi:10.1056/NEJMoa022473. PMid:12802024.
45. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791-1799. doi:10.1016/S0140-6736(11)61940-5. PMid:22480758.
46. Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin lymphoma (HL) (HD0607). 2012. doi:10.1016/S0140-6736(11)61940-5. Available at: http://clinicaltrials.gov/ct2/show/NCT00795613.
47. Fludeoxyglucose F 18-PET/CT imaging in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma. 2010. doi:10.1016/S0140- 6736(11)61940-5. Available at: http://clinicaltrials.gov/ct2/show/NCT00678327.
48. Fludeoxyglucose F 18-PET/CT imaging and combination chemotherapy with or without additional chemotherapy and G-CSF in treating patients with stage III or stage IV Hodgkin lymphoma. 2012. doi:10.1016/S0140-6736(11)61940-5. Available at: http://clinicaltrialsgov/ct2/show/NCT00822120.
49. Gallamini A, Patti C, Viviani S, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011; 152: 551-560. doi:10.1111/j.1365-2141.2010.08485.x. PMid:21166786.
50. HD18 for advanced stages in Hodgkins lymphoma. 2011. doi:10.1111/j.1365- 2141.2010.08485.x. Available at: http://clinicaltrials.gov/ct2/show/NCT00515554.
51. High-dose chemotherapy and stem cell transplantation, in patients PET-2 positive, after 2 courses of ABVD and comparison of RT versus no RT in PET-2 negative patients (HD0801). 2010. doi:10.1111/j.1365-2141.2010.08485.x. Available at: http://clinicaltrials.gov/ct2/show/NCT00784537.
52. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396-2406. doi:10.1056/NEJMoa022628. PMid:12802025.
53. Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 2008; 5: 543-556. doi:10.1038/ ncponc1186. PMid:18679394.
54. Moskowitz CH, Yahalom J, Zelenetz AD, et al. High-dose chemoradiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol 2010; 148: 890-897. doi:10.1111/j.1365-2141.2009.08037.x. PMid:20085577.
55. Moskowitz CH, Matasar MJ, Zelenetz AD, et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-crossresistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. Blood 2012; 119: 1665-1670. doi:10.1182/blood-2011-10-388058. PMid:22184409.
56. 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. Cancer 2011; 117: 1010-1018. doi:10.1002/cncr.25579. PMid:20960498.
57. Zanoni L, Cerci JJ, Fanti S. Use of PET/CT to evaluate response to therapy in lymphoma. Q J Nucl Med Mol Imaging 2011; 55: 633-647. PMid:22231583.
58. 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med 2010; 51: 1857-1862. doi:10.2967/jnumed.110.080556. PMid:21078789.
59. Kasamon YL, Wahl RL, Ziessman HA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant 2009; 15: 242-248. doi:10.1016/j.bbmt.2008.11.026. PMid:19167684.
60. Han HS, Escalon MP, Hsiao B, Serafini A, Lossos IS. High incidence of false-positive PET scans in patients with aggressive non- Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 2009; 20: 309-318. doi:10.1093/annonc/mdn629. PMid:18842613.
61. Yoo C, Lee DH, Kim JE, et al. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP. Ann Hematol 2011; 90: 797-802. doi:10.1007/s00277-010-1135-6. PMid:21181163.
62. Study evaluating the non-inferiority of a treatment adapted to the early response evaluated with 18F-FDG PET compared to a standard treatment, for patients aged from 18 to 80 years with low risk (aa IPI = 0) diffuse large B-cells non Hodgkin's lymphoma CD 20+. 2012. doi:10.1007/s00277-010-1135-6. Available at: http://clinicaltrials.gov/ct2/show/NCT01285765.
63. Therapy for patients with untreated age-adjusted international prognostic index low-intermediate risk, high-intermediate risk, or high risk diffuse large B cell lymphoma. 2012. doi:10.1007/s00277-010-1135-6. Available at: http://clinicaltrials.gov/ct2/show/NCT00712582.
64. Moskowitz CH, Schoder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010; 28: 1896-1903. doi:10.1200/JCO.2009.26.5942. PMid:20212248.
65. Lordick F, Ott K, Krause BJ, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007; 8: 797-805. doi:10.1016/S1470-2045(07)70244-9. PMid:17693134.
66. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20. doi:10.1056/NEJMoa055531. PMid:16822992.
67. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007; 8: 226-234. doi:10.1016/S1470- 2045(07)70039-6. PMid:17329193.
68. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984. doi:10.1056/NEJM199812313392704. PMid:9869669.
69. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006; 24: 4692-4698. doi:10.1200/JCO.2006.06.7801. PMid:16966684.
70. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19: 3058-3065. PMid:11408502.
71. Lordick F, Ott K, Krause BJ. New trends for staging and therapy for localized gastroesophageal cancer: the role of PET. Ann Oncol 2010; 21(Suppl 7): vii294-vii299. doi:10.1093/annonc/mdq289. PMid:20943631.
72. zum Buschenfelde CM, Herrmann K, Schuster T, et al. 18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. J Nucl Med 2011; 52: 1189-1196. doi:10.2967/jnumed.110.085803. PMid:21764790.
73. Lordick F, Ruers T, Aust DE, et al. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. Eur J Cancer 2008; 44: 1807-1819. doi:10.1016/j.ejca.2008.06.005. PMid:18640028.
74. Ott K, Herrmann K, Krause BJ, Lordick F. The value of PET imaging in patients with localized gastroesophageal cancer. Gastrointest Cancer Res 2008; 2: 287-294. PMid:19259277.
75. Lorenzen S, von Gall C, Stange A, et al. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the Oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer 2011; 11: 266. doi:10.1186/1471-2407-11-266. PMid:21702914.
76. PET-guided chemotherapy and hormone therapy in treating women with previously untreated invasive breast cancer. 2011. doi:10.1186/1471-2407-11-266. Available at: http://clinicaltrials.gov/ct2/show/NCT01330212.
77. Use of interim PET scan to modify therapy in advanced Hodgkin's lymphoma in order to improve outcomes. 2011. doi:10.1186/1471-2407-11-266. Available at: http://clinicaltrials.gov/ct2/show/NCT01304849.
78. Tailoring treatment for B cell non-Hodgkin's lymphoma based on PET scan results mid treatment. 2010. doi:10.1186/1471-2407-11-266. Available at: http://clinicaltrials.gov/ct2/show/NCT00324467.
79. Positron emission tomography guided therapy of aggressive non-Hodgkin's lymphomas (PETAL). 2011. doi:10.1186/1471-2407-11-266. Available at: http://clinicaltrials.gov/ct2/show/NCT00554164.